<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="35027">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01747720</url>
  </required_header>
  <id_info>
    <org_study_id>DR-002-1373</org_study_id>
    <nct_id>NCT01747720</nct_id>
  </id_info>
  <brief_title>Vitamin D and Mammographic Breast Density</brief_title>
  <acronym>EVIDENSE</acronym>
  <official_title>A Randomized Double-blind Placebo-controlled Trial of the Effect of Vitamin D Supplementation on Breast Density in Premenopausal Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Québec, CHU de Québec</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fondation du cancer du sein du Québec</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Québec, CHU de Québec</source>
  <oversight_info>
    <authority>Canada: Health Canada</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      There is some evidence that vitamin D could be used to reduce breast cancer risk. Randomized
      controlled trials would provide definitive evidence about this effect. However, trials with
      breast cancer as outcome are expensive and time-consuming. Use of surrogate outcomes has
      been advocated to accelerate progress in the identification of interventions that could
      prevent breast cancer. Mammographic breast density is one of the strongest breast cancer
      risk indicators and is already used as a surrogate outcome in several breast cancer
      prevention trials. The aim of this double-blind randomized controlled trial is to determine
      whether daily oral supplementation with vitamin D3 (1,000, 2,000 or 3,000 IU) over a period
      of 1 year reduces breast density in premenopausal women compared to placebo. A total of 376
      women (94 per arm) who live in Quebec City will be recruited. Showing that vitamin D reduces
      breast density would provide strong support for the idea that vitamin D can be a safe and
      inexpensive approach for the prevention of breast cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES

      Primary:

      - to determine whether adding oral supplementation with vitamin D3 (cholecalciferol) at
      doses of 1,000, 2,000 and 3,000 IU/d to baseline total vitamin D intake over a period of 12
      months reduces mammographic breast density among premenopausal women at moderate to high
      risk of breast cancer who reside in the Quebec City area, Canada.

      Secondary:

        -  to assess the net increase in 25(OH)D levels resulting from this vitamin D3
           supplementation;

        -  to document the compliance with, and safety of, supplementation with tested doses of
           vitamin D3 over one year.

      OUTLINE This study is a double-blind, placebo-controlled, randomized trial among
      premenopausal women who live in the Quebec City area and have ≥ 20% breast density at
      baseline.

      The intervention consists of the addition, over baseline total vitamin D intake from food
      and supplements, of three different doses of vitamin D3 (1000, 2000 or 3000 IU/day)  for a
      period of 12 months. There are four arms in the trial:

        -  Arm 1: 1,000 IU vitamin D3/d (1 tablet vitamin D 1000 IU + 2 tablets placebo);

        -  Arm 2: 2,000 IU vitamin D3/d (2 tablets vitamin D 1000 IU + 1 tablet placebo);

        -  Arm 3: 3,000 IU vitamin D3/d (3 tablets vitamin D 1000 IU);

        -  Arm 4: placebo (3 tablets placebo/d).

      Vitamin D tablets (1000 IU tablets) and the placebo tablets are undistinguishable in size,
      shape, color and taste, and are manufactured by the same company.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Mammographic breast density</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Difference in breast density between baseline and at 12 months</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">376</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Vitamin D3 (cholecalciferol) 1000 IU</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral vitamin D3 (cholecalciferol) supplementation, 1000 IU daily, for 12 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vitamin D3 (cholecalciferol) 2000 IU</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral vitamin D3 (cholecalciferol) supplementation, 2000 IU daily, for 12 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vitamin D3 (cholecalciferol) 3000 IU</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral vitamin D3 (cholecalciferol) supplementation, 3000 IU daily, for 12 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>daily, for 12 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin D3</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Vitamin D3 (cholecalciferol) 1000 IU</arm_group_label>
    <arm_group_label>Vitamin D3 (cholecalciferol) 2000 IU</arm_group_label>
    <arm_group_label>Vitamin D3 (cholecalciferol) 3000 IU</arm_group_label>
    <other_name>Cholecalciferol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  be premenopausal at baseline;

          -  have breast density of at least 20% at baseline;

          -  have normal baseline serum calcium (2,12-2,60 mmol/L) and serum creatinine (45-85
             μmol/L);

          -  agree to have her mammogram at 12 months of follow-up at the same mammography clinic
             (same site) as the one where the mammogram at recruitment was done.

        Exclusion Criteria:

          -  taking &gt; 400 IU/day of supplemental vitamin D and refusing to reduce (≤ 400 IU/day)
             or cease such intake;

          -  taking &gt; 600 mg/day of supplemental calcium and refusing to reduce (≤ 600 mg/day) or
             cease such intake;

          -  have contra-indications for use of vitamin D supplementation (hypersensitivity to
             vitamin D or  its analogues; a history of renal calculi or hypercalcemia,
             hypervitaminosis D);

          -  taking medication suspected to interact with vitamin D: frequent use of antacids
             containing magnesium or aluminium; regular use of anticonvulsants (phenytoin,
             phenobarbital), digoxin, cholestyramine, colestipol, orlistat, mineral oil;

          -  have a personal history of breast cancer;

          -  have a personal history of cancer other than non-melanoma skin cancer within 5 last
             years;

          -  have had breast reduction or augmentation including breast implantation (or planning
             to undergo such surgery during the trial);

          -  be pregnant or planning a pregnancy in the next year.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jacques Brisson, M.D., Sc.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre de recherche du CHU de Québec, et Faculté de médecine de l'Université Laval</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sylvie Bérubé, Ph.D.</last_name>
    <phone>418-682-7511</phone>
    <phone_ext>2175</phone_ext>
    <email>sylvie.berube@uresp.ulaval.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centre de recherche du CHU de Québec, Hôpital du Saint-Sacrement</name>
      <address>
        <city>Québec</city>
        <state>Quebec</state>
        <zip>G1S 4L8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sylvie Bérubé</last_name>
      <email>sylvie.berube@uresp.ulaval.ca</email>
    </contact>
    <investigator>
      <last_name>Jacques Brisson, M.D.,  Sc.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>http://www.evidense.ca/</url>
    <description>Study of Vitamin D and Breast Density</description>
  </link>
  <verification_date>December 2012</verification_date>
  <lastchanged_date>December 11, 2012</lastchanged_date>
  <firstreceived_date>December 10, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>breast cancer</keyword>
  <keyword>mammographic breast density</keyword>
  <keyword>vitamin D</keyword>
  <keyword>prevention</keyword>
  <keyword>randomized controlled trial</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cholecalciferol</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Vitamins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
